Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 479

Sort by

Sort Order Select

Journal Articles

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Blood (2025) 146 (20): 2443–2456.

https://doi.org/10.1182/blood.2024027822

Published: 2025

Includes: Supplemental data

Journal Articles

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Blood (2025) 146 (19): 2293–2305.

https://doi.org/10.1182/blood.2025028730

Published: 2025

Includes: Supplemental data

Journal Articles

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood (2025) 146 (14): 1677–1686.

https://doi.org/10.1182/blood.2025028330

Published: 2025

Includes: Supplemental data

Journal Articles

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

Blood (2025) 146 (14): 1693–1706.

https://doi.org/10.1182/blood.2024027540

Published: 2025

Includes: Supplemental data

Journal Articles

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Blood (2025) 145 (26): 3139–3152.

https://doi.org/10.1182/blood.2024027287

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Blood (2025) 145 (18): 1987–2001.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2025) 145 (11): 1126–1135.

https://doi.org/10.1182/blood.2024025464

Published: 2025

Includes: Supplemental data

Journal Articles

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Blood (2025) 145 (2): 234–243.

https://doi.org/10.1182/blood.2024026186

Published: 2025

Includes: Supplemental data

Journal Articles

An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Gianluca Asti, Saverio D'Amico, Luciana Carota, Davide Piscia, Francesco Casadei, Nono Saha Cyrille Merleau, Patricia Alonso de Apellániz, Anne Sophie Kubasch, Silke Gloaguen, Nicole Modler, Catalina Gonzalez Martin, Cesare Rollo, Juan Parras, Mattia Delleani, Elena Zazzetti, Elisabetta Sauta, Nico Curti, Nicolas Riccardo Derus, Gianluca Carlini, Daniele Dall'Olio, Claudia Sala, Lorenzo Dall'Olio, Luca Lanino, Giulia Maggioni, Alessia Campagna, Marilena Bicchieri, Arturo Bonometti, Cesare Lancellotti, Daoud Rahal, Luca Di Tommaso, Tiziana Sanavia, Piero Fariselli, Matteo Zampini, Matteo Brindisi, Victor Savevski, Uwe Platzbecker, Maria Diez-Campelo, Lin Pierre Zhao, Pierre Fenaux, Torsten Haferlach, Vincent Planat, Raffaella Colombatti, Maria del Mar Mañú-Pereira, Anders Krogh, Silvia Uribe, Santiago Zazo, Enrico Giampieri, Gastone Castellani, Matteo Giovanni Della Porta, Federico Alvarez

Blood (2024) 144 (Supplement 1): 4989.

https://doi.org/10.1182/blood-2024-205541

Published: 2024

Journal Articles

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Mikkael A. Sekeres, Hanny Al-Samkari, Hetty E. Carraway, Amy E. DeZern, Moshe Mittelman, Meredith Little, Vanessa Beynon, Xiaoshu Dai, Sal Sommakia, Jenny M. Despotovic, Parija Patel, Melissa Dibacco, Bruno Fattizzo, Eytan M. Stein, David Sallman, Austin G. Kulasekararaj, Uwe Platzbecker, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 6708.

https://doi.org/10.1182/blood-2024-203073

Published: 2024

Journal Articles

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2024-202101

Published: 2024

Journal Articles

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Blood (2024) 144 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2024-201317

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Uwe Platzbecker, Steven W Lane, Alice Garnier, Thomas Cluzeau, Odile Rauzy, Katharina S. S. Götze, Aristoteles Giagounidis, Deepak Singhal, Aicha Kopecky, Fatiha Chermat, Lionel Ades

Blood (2024) 144 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2024-194185

Published: 2024

Journal Articles

Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS

Anne Sophie Kubasch, Katharina Zoldan, Michael Cross, Marie Schneider, Jens Przybilla, Dirk Hasenclever, Klaus H Metzeler, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2024-199032

Published: 2024

Journal Articles

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Maximilian Alexander Rohnert, Jonas Schadt, Michael Kramer, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Désirée Kunadt, Jan Moritz Middeke, Lars Thielecke, Friedemann Uschner, Ingmar Glauche, Christian Thiede, Martin Bornhaeuser, Uta Oelschlaegel, Malte von Bonin, Uwe Platzbecker, Claudia D Baldus, Hubert Serve, Carsten Mueller-Tidow

Blood (2024) 144 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2024-194874

Published: 2024

Journal Articles

Predicting Progression Events in Multiple Myeloma from Routine Blood Work

Maximilian Ferle, Nora Grieb, Markus Kreuz, Uwe Platzbecker, Thomas Neumuth, Kristin Reiche, Alexander Oeser, Maximilian Merz

Blood (2024) 144 (Supplement 1): 7476.

https://doi.org/10.1182/blood-2024-192951

Published: 2024

Journal Articles

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jule Ussmann, Clara Wall, Lara Bischof, Jacob Jendro, Dominic Brauer, Donata Backhaus, Klaus H Metzeler, Marco Herling, Carmen Herling, Vladan Vucinic, Georg-Nikolaus Franke, Maximilian Merz, Timm Denecke, Uwe Platzbecker, Sebastian Schwind, Hans-Jonas Meyer, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2024-199943

Published: 2024

Journal Articles

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Vladan Vucinic, David Fandrei, Janine Kirchberg, Enrica Bach, Mandy Brueckner, Kathleen Friedrich, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Simone Heyn, Uwe Platzbecker, Maximilian Merz

Blood (2024) 144 (Supplement 1): 2094.

https://doi.org/10.1182/blood-2024-207117

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Predicting Progression Events in Multiple Myeloma from Routine Blood Work

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only